Taiwan Scientists Test Protein Enabling Colorectal, Cervical Cancers
This article was originally published in PharmAsia News
Tawainese researchers are testing an adaptor protein that causes cancer as a likely target for treating colorectal, cervical and possibly other cancers. The scientific team said the Eps8 protein had been linked to colorectal cancer two years ago, and then to cervical cancer, but now the researchers believe it enhances the proliferation of cells associated with the two cancers. By lowering the level of Eps8 in animals, the team achieved a decrease in tumor growth. (Click here for more
You may also be interested in...
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.